GlassScriptPhysician profile
Kenneth Weitung Lien
NPI 1396823092
$8,827.28
in general payments reported to CMS, 2019-2025
28 companies · $2,085 in 2025
The $2,085 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $797 · 2020: $798 · 2021: $1,295 · 2022: $1,058 · 2023: $1,418 · 2024: $1,376 · 2025: $2,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,777 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.79 |
| Education | $102.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,887.67 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,341.03 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $803.05 | 2019-2025 | |
| Greer Laboratories, INC. | $707.63 | 2019-2025 | Oralair |
| Regeneron Healthcare Solutions, INC. | $554.04 | 2020-2025 | Dupixent |
| Alk-Abello, INC | $393.60 | 2019-2025 | Odactra, Grastek, Alternaria Tenuis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.05 | 2019-2022 | |
| Genentech USA, INC. | $243.15 | 2019-2025 | Xolair |
| Covis Pharma Gmbh | $199.95 | 2020-2021 | |
| Amgen INC. | $194.47 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $159.17 | 2020-2025 | Hyqvia |
| Sanofi-Aventis U.S. LLC | $137.37 | 2022-2024 | |
| Lilly USA, LLC | $134.53 | 2025 | Ebglyss, Taltz |
| Biocryst US Sales Co., LLC | $102.32 | 2021-2025 | Orladeyo |
| Pfizer INC. | $100.82 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $95.82 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $80.12 | 2023-2025 | |
| Mylan Specialty L.P. | $62.26 | 2021-2023 | Yupelri |
| Shire North American Group INC | $61.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $51.91 | 2021-2023 | Airduo Digihaler |
| Kaleo, INC. | $49.99 | 2020-2023 | Auvi-Q |
| Optinose US, INC. | $46.78 | 2023-2025 | |
| Leo Pharma INC. | $32.42 | 2023 | Adbry |
| Exelixis INC. | $31.09 | 2025 | Cabometyx |
| Ars Pharmaceuticals Operations, INC. | $27.40 | 2025 | Neffy |
| Organon LLC | $22.17 | 2025 | Vtama |
| Aimmune Therapeutics, INC. | $22.17 | 2022 | |
| Abbvie INC. | $13.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Lien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.